Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation

Z. Jedlickova, C. Schmid, C. Koenecke, B. Hertenstein, H. Baurmann, R. Schwerdtfeger, J. Tischer, H. J. Kolb, M. Schleuning

Research output: Contribution to journalArticlepeer-review

78 Scopus citations


Adjuvant transfusion of donor lymphocytes (aDLT) may reduce the risk of relapse after allogeneic stem cell transplantation in high-risk AML. We performed a retrospective analysis on the safety and efficacy of aDLT in a cohort of 46 patients. To be eligible for aDLT, patients had to be in CR for at least 120 days from transplantation, off immunosuppression for ≥30 days and free of GvHD. Thirty-four patients with similar disease characteristics and fulfilling the same selection criteria served as controls. Median follow-up among aDLT recipients was 7.2 years. Ten patients (22%) relapsed inspite of aDLT, as compared with 53% in the control group. Induction of GvHD was the main complication. However, non-relapse mortality was low with patients dying from infection (n=2), severe chronic GvHD (n=1) and secondary malignancy (n=2). At the time of analysis, 31/46 aDLT recipients were alive in CR at a median of 5.7 years after first aDLT. Overall survival at 7 years after transplant was 67% as compared with 31% in the control group (P<0.001). In conclusion, aDLT is safe, when given in escalating doses to a well predefined group of patients. Long-term survival can be achieved.

Original languageEnglish
Pages (from-to)663-667
Number of pages5
JournalBone Marrow Transplantation
Issue number5
StatePublished - 1 May 2016
Externally publishedYes


Dive into the research topics of 'Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation'. Together they form a unique fingerprint.

Cite this